September 27, 2023
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
September 5, 2023
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer
September 5, 2023
Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
August 14, 2023
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results
August 3, 2023
Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer
May 25, 2023
Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors
May 9, 2023
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results
April 3, 2023
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 2, 2023
Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results
February 27, 2023
Xilio Therapeutics to Present at Upcoming Investor Conferences
Displaying 1 - 10 of 12